MX2023002125A - Proteínas de unión a antígenos con disulfuro no canónico en la región fab. - Google Patents

Proteínas de unión a antígenos con disulfuro no canónico en la región fab.

Info

Publication number
MX2023002125A
MX2023002125A MX2023002125A MX2023002125A MX2023002125A MX 2023002125 A MX2023002125 A MX 2023002125A MX 2023002125 A MX2023002125 A MX 2023002125A MX 2023002125 A MX2023002125 A MX 2023002125A MX 2023002125 A MX2023002125 A MX 2023002125A
Authority
MX
Mexico
Prior art keywords
fab region
antigen binding
binding proteins
canonical disulfide
multispecific
Prior art date
Application number
MX2023002125A
Other languages
English (en)
Inventor
Zhulun Wang
Fernando Garces
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2023002125A publication Critical patent/MX2023002125A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Abstract

La capacidad de generar una única construcción basada en anticuerpos que pueda reconocer múltiples dianas simultáneamente es fundamental para hacer avanzar muchos candidatos terapéuticos a la clínica. A menudo, esto implica un diseño de proteínas extenso con varios grados de éxito. En el caso de los anticuerpos multiespecíficos, la conducción del emparejamiento HC/LC en la región Fab representa uno de los desafíos más difíciles hasta el momento en el campo de la ingeniería multiespecífica. En el presente documento se describe el descubrimiento de una nueva ubicación para un enlace disulfuro no canónico y, como tal, la generación de una interfaz de cisteína asimétrica entre dos Fab presentes en la misma molécula que permitirá además la producción de multiespecíficos.
MX2023002125A 2020-08-20 2021-08-19 Proteínas de unión a antígenos con disulfuro no canónico en la región fab. MX2023002125A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063068306P 2020-08-20 2020-08-20
PCT/US2021/046770 WO2022040466A1 (en) 2020-08-20 2021-08-19 Antigen binding proteins with non-canonical disulfide in fab region

Publications (1)

Publication Number Publication Date
MX2023002125A true MX2023002125A (es) 2023-04-26

Family

ID=78032483

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002125A MX2023002125A (es) 2020-08-20 2021-08-19 Proteínas de unión a antígenos con disulfuro no canónico en la región fab.

Country Status (7)

Country Link
US (1) US20230322955A1 (es)
EP (1) EP4200338A1 (es)
JP (1) JP2023538897A (es)
AU (1) AU2021329374A1 (es)
CA (1) CA3191710A1 (es)
MX (1) MX2023002125A (es)
WO (1) WO2022040466A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4347655A1 (en) 2021-06-04 2024-04-10 Amgen Inc. Anti-ccr8 antibodies and uses thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JPH06508035A (ja) 1991-06-14 1994-09-14 ディーエヌエックス　コーポレーション トランスジェニックブタにおけるヒトヘモグロビンの生産
WO1993001227A1 (en) 1991-07-08 1993-01-21 University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
ES2304786T3 (es) 1995-04-27 2008-10-16 Amgen Fremont Inc. Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados.
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
US8280711B2 (en) 2007-03-12 2012-10-02 ESBATech, an Alcon Biomedical Research Unit, LLC. Sequence based engineering and optimization of single chain antibodies
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
US8793074B2 (en) 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
NZ581468A (en) 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
AU2011257121A1 (en) 2010-05-27 2013-01-10 Genmab A/S Monoclonal antibodies against HER2
CN104114579B (zh) 2011-10-27 2020-01-24 健玛保 异二聚体蛋白的生成
CR20180365A (es) * 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
CN109475627B (zh) * 2016-05-26 2023-01-06 齐鲁普吉湾生物治疗公司 抗体混合物
WO2019178539A1 (en) * 2018-03-16 2019-09-19 Ngm Biopharmaceuticals, Inc. Bispecific antibodies

Also Published As

Publication number Publication date
JP2023538897A (ja) 2023-09-12
CA3191710A1 (en) 2022-02-24
US20230322955A1 (en) 2023-10-12
EP4200338A1 (en) 2023-06-28
WO2022040466A1 (en) 2022-02-24
AU2021329374A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
NZ602256A (en) Monoclonal antibodies against the rgm a protein and uses thereof
EA201391753A1 (ru) Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
EP3539982A3 (en) Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
WO2013054331A8 (en) Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
MX2015012059A (es) Anticuerpos biespecificos tetravalentes.
MX2014014065A (es) Metodo para la seleccion y produccion de moleculas terapeuticas hechas a la medida, selectivas y multiespecificas que comprenden al menos dos diferentes entidades de direccionamiento y usos de las mismas.
EA201200526A1 (ru) Поливалентные антитела, стабилизированные дисульфидом
EA201591049A1 (ru) Способы получения конъюгатов дисульфидсодержащих белков
RS52452B (en) Antibodies and Immunoconjugates and Their Use
RS51908B (en) CLOSTRIDIUM DIFFICILE TOXIN ANTIBODIES AND THEIR USES
MX2023002125A (es) Proteínas de unión a antígenos con disulfuro no canónico en la región fab.
EA201691075A1 (ru) Способы оксимной конъюгации с кетон-модифицированными полипептидами
MY164906A (en) Dual variable region antibody-like binding proteins having cross-over binding region orientation
CL2009000441A1 (es) Metodo para modificar el punto isoelectrico (pl) de un péptido que comprende una region variable de un anticuerpo mediante la sustitucion de aminoacidos en la region cdr, anticuerpos que tiene un pl modificados en las regiones cdr, util para aumentar el tiempo de residencia en el plasma.
NZ602676A (en) Anti-vla-4 antibodies
WO2009088924A3 (en) Methods and materials for targeted affinity enhancement
EA201690171A1 (ru) Улучшенный способ получения моноклональных антител
MY155144A (en) NEW ANTIBODIES SPECIFIC OF THE ß-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS
MX2023004054A (es) Anticuerpos anti-dectina 1 y metodos de uso de los mismos.
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
UA117493C2 (uk) Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання
WO2018231339A3 (en) TYROSINE PHOSPHORYLATED ANTI-PD-1 ANTIBODIES AND USES THEREOF
WO2019025865A3 (en) METHODS AND COMPOSITIONS FOR LIGAND-DIRECTED ANTIBODY DESIGN
MX2023007583A (es) Metodos para obtener anticuerpos que se unen a proteinas transmembranarias y celulas que los producen.
MX2023005379A (es) Enlazadores novedosos de dominios de union a antigenos multiespecificos.